MGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Metagenomi Therapeutics Inc (MGX) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available. The lack of positive news, weak financial performance, and hedge fund selling trends suggest caution. While technical indicators are neutral to slightly positive, they do not strongly support a buy decision. The absence of Intellectia Proprietary Trading Signals further diminishes the case for immediate investment.
The MACD is positive and expanding (0.0172), indicating slight bullish momentum. RSI is neutral at 67.619, and moving averages are converging, suggesting no clear trend. The pre-market price of $1.6 is close to the first resistance level (R1: 1.579), indicating limited upside potential in the short term.
NULL identified. No recent news or significant insider buying.
Hedge funds are selling heavily, with a 323.12% increase in selling over the last quarter. Financial performance shows a significant revenue drop (-24.80% YoY) in Q3 2025, despite slight improvements in net income and EPS.
In Q3 2025, revenue dropped significantly by -24.80% YoY to $8,659,000. Net income improved slightly but remains negative at -$20,393,000 (up 8.63% YoY). EPS also improved to -0.55 (up 7.84% YoY). Gross margin remains at 100%. Overall, the financials indicate weak growth trends.
No data available for analyst ratings or price target changes.
